My ePortfolio Register   

Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.03.17
Views: 406
Rating:

Dr David Siegel - John Theurer Cancer Center, Hackensack, USA

Dr Siegel talks to ecancer at the 16th International Myeloma Workshop about the ASPIRE trial, looking at carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

He also discusses the ENDEAVOUR trial looking at carfilzomib in combination with low-dose dexamethasone (Kd), versus bortezomib with low-dose dexamethasone (Vd) in patients whose multiple myeloma has relapsed after at least one, but not more than three prior therapeutic regimens. 

Since presentation at ASH 2015 the data from both trials has matured. Consistent with the primary analyses, the results show that incorporation of carfilzomib into treatment regimens in patients with relapsed or refractory multiple myeloma results in clinically meaningful improvements in progression free survival and a favourable benefit–risk profile.

Read more here.

Carfilzomib is also being trialled combination therapies for for newly diagnosed myeloma, as discussed by Dr Boccia here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence